• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>MedImmune

MedImmune

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Manhattan Scientifics Reaches the Fork (Falk) in the Road

    Manhattan Scientifics Reaches the Fork (Falk) in the Road

  2. Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

    Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market

  3. AstraZeneca Starts New Study for Asthma Drug Tralokinumab

    AstraZeneca Starts New Study for Asthma Drug Tralokinumab

  4. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

    Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials

  5. Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin

    Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin

  6. Morningstar Indexes: Weekly Market Report

    Week ending April 27: Quarterly earnings continue to boost market's spirits. 

  7. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  8. Services Super Sector: Major Themes

    Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...

  9. Biotech Investing for the Long Haul

    Three ways to separate long-term winners from stocks that fizzle.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.